After a delay, the Alpha-3 study faces an April futility analysis.
ApexOnco Front Page
Recent articles
A first-in-human trial of PRT12396 starts next month.
The holiday period included Genmab’s discontinuation of acasunlimab.
A deal with Jacobio is worth $100m up front.
Nenocorilant features among the latest industry projects newly into phase 1.
The private ADC company is being wound down.
Two new PD-(L)1 x VEGF projects have entered the clinic.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
